Literature DB >> 22615288

High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.

Heather A Wroblewski1, Richard J Kovacs, Joanna R Kingery, Brian R Overholser, James E Tisdale.   

Abstract

Cardiac toxicity may be associated with drugs used for malaria. Torsades de pointes (TdP) is a well-known adverse effect of quinidine when used for atrial fibrillation. Intravenous quinidine doses for resistant malaria are 2 to 3 times higher than those used for arrhythmias. Among 6 patients receiving quinidine for malaria or babesiosis, 4 developed QT interval prolongation and 2 experienced TdP. Clinicians should be aware that recommended doses of quinidine for malaria carry a high TdP risk.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22615288      PMCID： PMC3421624          DOI： 10.1128/AAC.06396-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G de Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

2.  Severe cardiac toxicity due to halofantrine: importance of underlying heart disease.

Authors:  Olivier Bouchaud; Fabrice Bruneel; Ricarda Schiemann; Gilles Peytavin; Jean P Coulaud
Journal:  J Travel Med       Date:  2002 Jul-Aug       Impact factor: 8.490

3.  Preferred QT correction formula for the assessment of drug-induced QT interval prolongation.

Authors:  John Chiladakis; Andreas Kalogeropoulos; Panagiotis Arvanitis; Nikolaos Koutsogiannis; Fani Zagli; Dimitrios Alexopoulos
Journal:  J Cardiovasc Electrophysiol       Date:  2010-03-05

4.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

5.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Europace       Date:  2010-10       Impact factor: 5.214

6.  Malaria surveillance--United States, 2010.

Authors:  Sonja Mali; S Patrick Kachur; Paul M Arguin
Journal:  MMWR Surveill Summ       Date:  2012-03-02

7.  Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series.

Authors:  N M Allen LaPointe; P Li
Journal:  Am Heart J       Date:  2000-01       Impact factor: 4.749

8.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.

Authors:  Anne M Gillis; Atul Verma; Mario Talajic; Stanley Nattel; Paul Dorian
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

Review 9.  Babesiosis. Two atypical cases from Minnesota and a review.

Authors:  Suman Setty; Zena Khalil; Pamela Schori; Miguel Azar; Patricia Ferrieri
Journal:  Am J Clin Pathol       Date:  2003-10       Impact factor: 2.493

Review 10.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447
View more
  6 in total

1.  Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.

Authors:  Ksenia Blinova; Jayna Stohlman; Jose Vicente; Dulciana Chan; Lars Johannesen; Maria P Hortigon-Vinagre; Victor Zamora; Godfrey Smith; William J Crumb; Li Pang; Beverly Lyn-Cook; James Ross; Mathew Brock; Stacie Chvatal; Daniel Millard; Loriano Galeotti; Norman Stockbridge; David G Strauss
Journal:  Toxicol Sci       Date:  2016-10-03       Impact factor: 4.849

2.  Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol.

Authors:  Patrick S Twomey; Bryan L Smith; Cathy McDermott; Anne Novitt-Moreno; William McCarthy; S Patrick Kachur; Paul M Arguin
Journal:  Ann Intern Med       Date:  2015-10-06       Impact factor: 25.391

Review 3.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

Review 4.  Treating severe malaria in pregnancy: a review of the evidence.

Authors:  Stephanie D Kovacs; Marcus J Rijken; Andy Stergachis
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

5.  Stereoselective Blockage of Quinidine and Quinine in the hERG Channel and the Effect of Their Rescue Potency on Drug-Induced hERG Trafficking Defect.

Authors:  Meng Yan; Pan Fan; Yanhui Shi; Lifang Feng; Junnan Wang; Ge Zhan; Baoxin Li
Journal:  Int J Mol Sci       Date:  2016-09-28       Impact factor: 5.923

Review 6.  Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.

Authors:  Paz Ovics; Danielle Regev; Polina Baskin; Mor Davidor; Yuval Shemer; Shunit Neeman; Yael Ben-Haim; Ofer Binah
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.